According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), ABVC BioPharma, Inc. has identified significant deficiencies in its internal control over financial reporting for the fiscal year 2025.

老虎证券2026/03/03 22:14

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

EUR/GBP Price Forecast: Rejection at 0.8500 leaves yearly low at 0.8455 exposed

FXStreet•2026/10/07 07:54

Dalio issues another warning: AI is a “classic bubble,” and the tipping point of the bubble is “very close.”

Dalio warns that artificial intelligence is in a "classic bubble," as rising interest rates combined with liquidity demands are pushing it close to the breaking point; he states, "We are already very close to that point."

智通财经•2026/10/07 07:43

A cryptocurrency exchange is considering launching tokenized stocks.

AiCoin•2026/10/07 07:37

A chart: Overview of "pivot points + long and short positions signals" for gold, crude oil, forex, and stock indices on October 7, 2026

汇通财经•2026/10/07 07:35